Compounds and methods targeting interleukin-19
AssigneeEli Lilly and Company
InventorsRichard Earl HIGGS, JR., Robert John KONRAD, Brian Jeffrey NICKOLOFF, Robert William SIEGEL, II
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds and methods targeting human interleukin-19, including therapeutic antibodies, pharmaceutical compositions and diagnostic applications useful in the field of immune-mediated diseases including psoriasis, atopic dermatitis, psoriatic arthritis, bronchial asthma and diabetic nephropathy.
Claims8
An antibody which binds to human IL-19, said antibody comprising a light chain variable region (LCVR) and a heavy chain variable region (HCVR), wherein the LCVR comprises complementarity determining regions (CDRs) LCDR1, LCDR2, and LCDR3 and the HCVR comprises CDRs HCDR1, HCDR2 and HCDR3 selected from:
- a. a grouping of LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, and HCDR3 having at least 95% amino acid sequence homology to the amino acid sequence of a grouping of LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, and HCDR3 provided in Table 1;
- b. grouping of LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, and HCDR3 having at least 95% amino acid sequence homology to the amino acid sequence of a grouping of LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, and HCDR3 provided in Table 2;
- or
- c. grouping of LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, and HCDR3 having at least 95% amino acid sequence homology to the amino acid sequence of a grouping of LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, and HCDR3 provided in Table 3.
Dependencies are inferred from the claim text.